Navigating HCM Management Paradigms with Dr Masri
EP 96: Conversations about Hypertrophic Cardiomyopathy: Navigating HCM Management Paradigms with Dr Masri

Average (ratings)
No ratings
 
  Your rating

In the second episode of our mini-series "Conversations about Hypertrophic Cardiomyopathy", Dr Ankur Kalra sat down with Dr Ahmad Masri to have a deep-dive into the management paradigms of hypertrophic cardiomyopathy (HCM), considering the evolution of medical therapy in recent years. Dr Ahmad Masri is a Cardiologist and the Director of OHSU Hypertrophic Cardiomyopathy Center.

 

This series is supported by an unrestricted educational grant from Bristol Myers Squibb. Please see www.camzyosrems.com for important safety information.

 

Dr Kalra invites Dr Masri to guide us through his decision-making process in evaluating medical and surgical options in patients with obstructive hypertrophic cardiomyopathy. Dr Masri delves into first and second-line treatment strategies while exploring the significance of FDA-approved cardiac myosin inhibitors in the management of hypertrophic cardiomyopathy. Dr Kalra asks Dr Masri about the practical office-based clinical course for patients deemed suitable candidates to receive mavacamten. Dr Masri provides a clear and practical outline of what it entails to opt for this second-line medical therapy including the REMS programme required for therapy (www.camzyosrems.com). Dr Masri highlights the importance of looking at HCM patients holistically to find the treatment which best fits their circumstances and preferences in choosing surgical and medical therapy options.

 

What are the available management options for patients with HCM? How does Dr Masri approach shared decision-making in the management of HCM? What are some of the practical considerations regarding the cardiac myosin inhibitor, mavacamten?

 

This content is intended for US-based physicians.


Read MoreRead Less
Share

This series is supported by an unrestricted educational grant from Bristol Myers Squibb.

Read MoreRead Less
Up Next
Differential Diagnosis, Genetic Testing & Patient-centric Therapy
EP97 • Aug 07, 2023 • 44m 40s
In the finale of our series "Conversations about Hypertrophic Cardiomyopathy", Dr Ankur Kalra welcomes, Dr Anjali Tiku Owens, for a dynamic and practical discussion.

Dr Owens is Medical Director of the Center for Inherited Cardiac Disease and Associate Professor of Medicine at the Hospital of the University of Pennsylvania.

This series is supported by an unrestricted educational grant from Bristol Myers Squibb. Please see www.camzyosrems.com for important safety information.

This content is intended for US-based physicians.
Read More
All Episodes
01: Conduction Abnormalities After TAVR/TAVI With Chad Kliger
EP01 • Apr 23, 2020 • 27m 44s
In our first episode, Ankur explains his vision for and inspiration to start ‘Parallax’, and speaks with Chad Kliger from Lenox Hill Hospital in New York about conduction abnormalities after transcatheter aortic valve replacement (TAVR/TAVI), a review article published in US Cardiology Review 13.1 Ankur and Chad look at conduction abnormalities after TAVR/TAVI with a focus on basic conduction system anatomy in relation to the aortic valve, the mechanism, incidence, predisposing factors for occurrence, impact on mortality and finally, proposed treatment algorithms for management. Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
Read More
EP 41: Mallory Abbott on Ebstein’s Anomaly, Self-Care & Gratitude
EP41 • Feb 09, 2021 • 42m 26s
Mallory was not prepared when she underwent her first heart surgery in seventh grade: She was hoping to regain her stamina, instead she experienced what she describes as a loss of self. Mallory was born with a rare heart disease called a Ebstein’s anomaly.
Read More
40: Mentorship, Reflection & the Journey of Mandeep R Mehra
EP40 • Jan 25, 2021 • 46m 33s
How does Dr Mehra think about building opportunities? What were his formative experiences? How does he think about the role of mentorship in medicine? What is Dr Mehra’s message to our listeners?Dr Mehra does not frame his experiences as failures or successes; he looks at all events with one question in mind: What can I learn from this?

In this week’s episode Ankur’s guest is Dr Mandeep R Mehra, Medical Director of Brigham Heart and Vascular Center and Professor of Medicine at Harvard Medical School.
Read More
EP 39: The Year 2020 in Review with Sukh Nijjer
EP39 • Jan 21, 2021 • 1h 2m 19s
In the first Parallax episode of 2021, Ankur welcomed back Sukh Nijjer from Imperial College London to review the most impactful events and advances in cardiology from 2020.

Which COVID19 patients require risk stratification with a stress test? What are the take-home messages for physicians taking care of patients diagnosed with COVID19? What were the key trials of 2020? What can we learn from the negative results of the STRENGHT study? How have studies like STOP-AF influenced clinical practice?
Read More
38: Martin B Leon on CRF, Mentorship and the Lessons of 2020
EP38 • Dec 17, 2020 • 27m 6s
In the Season 2 finale, Ankur Kalra is joined by the legendary Martin B Leon, Professor at Columbia University, director of the TCT and chairman emeritus of the CRF.

What makes Dr Martin B Leon tick? What is his message to cardiologists and/or researchers at the beginning of their careers? How did the pandemic and his work as a clinician in New York change his perspective?
Read More
37: Lindsay’s Law: From Ballerina to Health Advocate
EP37 • Dec 30, 2020 • 32m 15s
This week Parallax welcomed its first non-physician/researcher guest: health advocate Lindsay Davis. Lindsay, ballerina with ambitions to study at Julliard, was experiencing the symptoms of hypertrophic cardiomyopathy (HCM) from her early teens, but she had not been diagnosed until she was 17.

In this episode Ankur asks Lindsay about her treatment path. Lindsay recalls her own journey to taking control of her condition and the important role of information in patient adherence. Lindsay, former Miss Ohio, talks how she used the pageant to create awareness. Lindsay talks about work in state legislation and her plans for 2021.
Read More